Fragile X syndrome: Causes, diagnosis, mechanisms, and therapeutics

Claudia Bagni, Flora Tassone, Giovanni Neri, Randi J Hagerman

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Fragile X syndrome (FXS) is the most frequent form of inherited intellectual disability and is also linked to other neurologic and psychiatric disorders. FXS is caused by a triplet expansion that inhibits expression of the FMR1 gene; the gene product, FMRP, regulates mRNA metabolism in the brain and thus controls the expression of key molecules involved in receptor signaling and spine morphology. While there is no definitive cure for FXS, the understanding of FMRP function has paved the way for rational treatment designs that could potentially reverse many of the neurobiological changes observed in FXS. Additionally, behavioral, pharmacological, and cognitive interventions can raise the quality of life for both patients and their families.

Original languageEnglish (US)
Pages (from-to)4314-4322
Number of pages9
JournalJournal of Clinical Investigation
Volume122
Issue number12
DOIs
StatePublished - Dec 3 2012

Fingerprint

Fragile X Syndrome
Therapeutics
Nervous System Diseases
Intellectual Disability
Psychiatry
Spine
Quality of Life
Pharmacology
Gene Expression
Messenger RNA
Brain
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fragile X syndrome : Causes, diagnosis, mechanisms, and therapeutics. / Bagni, Claudia; Tassone, Flora; Neri, Giovanni; Hagerman, Randi J.

In: Journal of Clinical Investigation, Vol. 122, No. 12, 03.12.2012, p. 4314-4322.

Research output: Contribution to journalArticle

@article{03ff5dbc9dcb4a1aa8d7f33ac7ea72a2,
title = "Fragile X syndrome: Causes, diagnosis, mechanisms, and therapeutics",
abstract = "Fragile X syndrome (FXS) is the most frequent form of inherited intellectual disability and is also linked to other neurologic and psychiatric disorders. FXS is caused by a triplet expansion that inhibits expression of the FMR1 gene; the gene product, FMRP, regulates mRNA metabolism in the brain and thus controls the expression of key molecules involved in receptor signaling and spine morphology. While there is no definitive cure for FXS, the understanding of FMRP function has paved the way for rational treatment designs that could potentially reverse many of the neurobiological changes observed in FXS. Additionally, behavioral, pharmacological, and cognitive interventions can raise the quality of life for both patients and their families.",
author = "Claudia Bagni and Flora Tassone and Giovanni Neri and Hagerman, {Randi J}",
year = "2012",
month = "12",
day = "3",
doi = "10.1172/JCI63141",
language = "English (US)",
volume = "122",
pages = "4314--4322",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "12",

}

TY - JOUR

T1 - Fragile X syndrome

T2 - Causes, diagnosis, mechanisms, and therapeutics

AU - Bagni, Claudia

AU - Tassone, Flora

AU - Neri, Giovanni

AU - Hagerman, Randi J

PY - 2012/12/3

Y1 - 2012/12/3

N2 - Fragile X syndrome (FXS) is the most frequent form of inherited intellectual disability and is also linked to other neurologic and psychiatric disorders. FXS is caused by a triplet expansion that inhibits expression of the FMR1 gene; the gene product, FMRP, regulates mRNA metabolism in the brain and thus controls the expression of key molecules involved in receptor signaling and spine morphology. While there is no definitive cure for FXS, the understanding of FMRP function has paved the way for rational treatment designs that could potentially reverse many of the neurobiological changes observed in FXS. Additionally, behavioral, pharmacological, and cognitive interventions can raise the quality of life for both patients and their families.

AB - Fragile X syndrome (FXS) is the most frequent form of inherited intellectual disability and is also linked to other neurologic and psychiatric disorders. FXS is caused by a triplet expansion that inhibits expression of the FMR1 gene; the gene product, FMRP, regulates mRNA metabolism in the brain and thus controls the expression of key molecules involved in receptor signaling and spine morphology. While there is no definitive cure for FXS, the understanding of FMRP function has paved the way for rational treatment designs that could potentially reverse many of the neurobiological changes observed in FXS. Additionally, behavioral, pharmacological, and cognitive interventions can raise the quality of life for both patients and their families.

UR - http://www.scopus.com/inward/record.url?scp=84870543150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870543150&partnerID=8YFLogxK

U2 - 10.1172/JCI63141

DO - 10.1172/JCI63141

M3 - Article

C2 - 23202739

AN - SCOPUS:84870543150

VL - 122

SP - 4314

EP - 4322

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 12

ER -